Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3031207 · 1 trial · 1 indication
AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.
| Arm | Type | Description |
|---|---|---|
| LY3031207 | EXPERIMENTAL | Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally. |
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose. |
| Celecoxib | ACTIVE_COMPARATOR | Single 400mg dose of celecoxib administered orally on one occasion. |
| Name | Type | Description |
|---|---|---|
| LY3031207 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Celecoxib | DRUG | Administered orally |
Inclusion Criteria: * Male subjects agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product * Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy w...
LY3031207 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early clinical development.
LY3031207 is made by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the developer and sponsor of the compound's clinical program.
LY3031207 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The program's only listed trial, NCT01449630, has been completed, and no active trials are currently listed for this compound.
LY3031207 has been evaluated in one clinical trial, NCT01449630, titled A Study of LY3031207 in Healthy Subjects. The Phase 1 trial was completed in the United States and enrolled 29 healthy adult volunteers. It was randomized, double-blind, and placebo-controlled.
The Phase 1 trial of LY3031207, NCT01449630, was a randomized, double-blind, placebo-controlled study conducted in the United States. It enrolled 29 healthy volunteers aged 18 years and older, with both sexes eligible. The study has been completed.